Sensome, the pioneer of microsensing technology for real-time, intra-operative tissue analysis, today announced positive results from its first-in-human INSPECT study evaluating its microsensor ...
ImmunityBio Inc (NASDAQ:IBRX) shares rose 8.6% in premarket trading Wednesday after the company announced the FDA accepted its supplemental Biologics License Application for ANKTIVA in combination ...
Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...
The two factors associated with needing larger final margins were older patient age and larger average preoperative tumor diameters, according to a single-center review of 530 primary MIS cases.
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results ...
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales ...
Dr. Elisa Port draws on patient stories like Martin's and Evert's and 25 years of experience for a new book on breast care ...
ImmunityBio Inc. IBRX presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the ...
Researchers have found in a retrospective cohort study of patients with non–muscle-invasive bladder cancer (NMIBC) treated ...
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response ...
Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results